Literature DB >> 17520519

Guidelines for therapy of autoimmune liver disease.

Hiromi Ishibashi1, Atsumasa Komori, Shinji Shimoda, M Eric Gershwin.   

Abstract

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroid-sparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopic, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520519     DOI: 10.1055/s-2007-979472

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  11 in total

1.  Formation of large vacuoles induced by cooperative effects of oncostatin M and dexamethasone in human fetal liver cells.

Authors:  Tamihide Matsunaga; Mie Toba; Tsuyoshi Teramoto; Mitsue Mizuya; Kaori Aikawa; Shigeru Ohmori
Journal:  Med Mol Morphol       Date:  2008-05-11       Impact factor: 2.309

Review 2.  Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.

Authors:  Murad Aljiffry; Paul D Renfrew; Mark J Walsh; Marie Laryea; Michele Molinari
Journal:  HPB (Oxford)       Date:  2011-02       Impact factor: 3.647

Review 3.  Impact of microbes on autoimmune diseases.

Authors:  Claudia Danzer; Jochen Mattner
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-02-16       Impact factor: 4.291

Review 4.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

5.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

Review 6.  The use of marine-derived bioactive compounds as potential hepatoprotective agents.

Authors:  Dileep G Nair; Ralf Weiskirchen; Salma K Al-Musharafi
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 7.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

8.  Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

Authors:  Angela Douglass; Karen Wallace; Matthew Koruth; Caroline Barelle; Andrew J Porter; Matthew C Wright
Journal:  Hepatol Int       Date:  2008-09-03       Impact factor: 6.047

9.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Authors:  Emina Halilbasic; Romina Fiorotto; Peter Fickert; Hanns-Ulrich Marschall; Tarek Moustafa; Carlo Spirli; Andrea Fuchsbichler; Judith Gumhold; Dagmar Silbert; Kurt Zatloukal; Cord Langner; Uday Maitra; Helmut Denk; Alan F Hofmann; Mario Strazzabosco; Michael Trauner
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

10.  Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Authors:  Anna Baghdasaryan; Thierry Claudel; Judith Gumhold; Dagmar Silbert; Luciano Adorini; Aldo Roda; Stefania Vecchiotti; Frank J Gonzalez; Kristina Schoonjans; Mario Strazzabosco; Peter Fickert; Michael Trauner
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.